Synthesis and biological evaluation of [18F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter by Jauregui-Osoro, Maite et al.
ORIGINAL ARTICLE
Synthesis and biological evaluation of [
18F]tetrafluoroborate:
a PET imaging agent for thyroid disease and reporter gene
imaging of the sodium/iodide symporter
Maite Jauregui-Osoro & Kavitha Sunassee & Amanda J. Weeks & David J. Berry &
Rowena L. Paul & Marcel Cleij & Jasvinder Paul Banga & Michael J. O’Doherty &
Paul K. Marsden & Susan E. M. Clarke & James R. Ballinger & Istvan Szanda &
Sheue-Yann Cheng & Philip J. Blower
Received: 4 February 2010 /Accepted: 3 June 2010 /Published online: 25 June 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Purpose The human sodium/iodide symporter (hNIS) is a
well-established target in thyroid disease and reporter gene
imaging using gamma emitters
123I-iodide,
131I-iodide
and
99mTc-pertechnetate. However, no PET imaging agent
is routinely available. The aim of this study was to prepare
and evaluate
18F-labelled tetrafluoroborate ([
18F]TFB) for
PET imaging of hNIS.
Methods [
18F]TFB was prepared by isotopic exchange of
BF4
− with [
18F]fluoride in hot hydrochloric acid and
purified using an alumina column. Its identity, purity and
stability in serum were determined by HPLC, thin-layer
chromatography (TLC) and mass spectrometry. Its interac-
tion with NIS was assessed in vitro using FRTL-5 rat
thyroid cells, with and without stimulation by thyroid-
stimulating hormone (TSH), in the presence and absence of
perchlorate. Biodistribution and PET imaging studies were
performed using BALB/c mice, with and without perchlo-
rate inhibition.
Results [
18F]TFB was readily prepared with specific activ-
ity of 10 GBq/mg. It showed rapid accumulation in FRTL-5
cells that was stimulated by TSH and inhibited by
perchlorate, and rapid specific accumulation in vivo in
thyroid (SUV=72 after 1 h) and stomach that was inhibited
95% by perchlorate.
Conclusion [
18F]TFB is an easily prepared PET imaging
agent for rodent NIS and should be evaluated for hNIS PET
imaging in humans.
Keywords
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Introduction
Historically, molecular imaging of the human sodium/
iodide symporter (hNIS) [1, 2] with radioiodide has made
a major contribution to the management of thyroid cancer
and the development of nuclear medicine [3, 4]. The
success of [
131I]iodide treatment for thyroid cancer and
hyperthyroidism founded the field of therapeutic nuclear
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131I]iodide and [
123I]iodide
has been fundamental to diagnosis of disease and monitor-
ing treatment outcomes for over half a century. More
recently, radioiodine imaging has found a role in dose
planning in radionuclide therapy [5, 6]. In addition, recently
hNIS has taken on a new research role as a reporter gene
[7–9] in gene therapy and imaging of cell migration and
differentiation. Reporter gene imaging with radioiodide
SPECT is feasible because hNIS is normally expressed in
only a few tissues (thyroid, gastric mucosa, salivary glands,
kidneys and lactating breast) [10]. [
99mTc]pertechnetate
offers a more readily available and cheaper substitute for
SPECT imaging where reduced radiation absorbed dose is
important.
Despite the historical importance of hNIS imaging,
current methods have limitations. SPECT has limited
resolution and sensitivity for detecting low volume
disease, especially if normal functioning thyroid rem-
nants remain. With
131I, and to a lesser extent with
123I,
“stunning” occurs—low activities administered for imag-
ing may reduce the effectiveness of the therapy dose
of
131I[ 4]. The half-lives of both iodine radionuclides are
longer than required for imaging, so absorbed radiation
doses are unnecessarily high. Resolution and sensitivity of
PETare significantly better than those of SPECT, resulting
in better delineation of small regions of tracer uptake or
lack of uptake. Better quantification of the absolute
amount of tracer in small regions is also possible with
PET. A PET alternative to SPECT as the primary hNIS
imaging procedure could thus improve sensitivity of
detection of metastases and cold nodules, tumour volume
measurement and hNIS reporter gene imaging.
Current options for PET imaging of hNIS expression
are very limited. The positron emitter [
124I]iodide [5, 6,
8, 11–16] has shown better sensitivity for detection of
metastases than SPECT [13]. Volume determination, and
hence accurate dosimetry, was feasible for lesions as
small as 13 mm diameter [5, 16].
124I, however, suffers
from several disadvantages that prevent routine diagnostic
use. The low positron yield (23%) and long half-life mean
that the radiation dose per unit positron yield from
124Ii s
approximately 18 times that from
18F. This is com-
pounded by high positron energy (Emax=2.14 MeV) and
high energy gamma emission, both of which degrade
image quality. Moreover, its availability is severely
limited and its production relatively complex. [
94mTc]
pertechnetate [17] could be considered, but is not a
plausible replacement because it is not widely available
and its production is complex. The ideal radionuclide
would be
18F, as it is readily available, and has a half-life
(110 min) compatible with typical imaging times and a
low energy (Emax=0.634 MeV), high yield (97%) posi-
tron emission.
Many non-natural substrates for NIS are known, some of
which are important medically as iodide uptake inhibitors
(e.g. perchlorate) [2, 18–21]. [
99mTc]pertechnetate is used
for thyroid SPECT, and [
188Re]perrhenate [22, 23] and
[
211At]astatide [24, 25] have been proposed for radionu-
clide therapy [22–24, 26, 27]. The key shared physico-
chemical features are uninegative charge, similar ionic
radius/volume and similar space-filling properties, i.e.
roughly spherical (e.g. tetrahedral, non-dipolar) [2, 19].
Smaller anions such as fluoride, chloride and bromide do
not compete as substrates [2]. Tetrafluoroborate (TFB) [19]
is a fluorine-containing ion that interacts with NIS. It has
not been used for PET imaging, but in the 1950s and early
1960s, before both the advent of clinical PET and the
identification and characterisation of hNIS [2], Anbar et al.
produced data suggesting to us that labelled TFB would
have good potential for thyroid imaging [18, 19, 28]: TFB
inhibits iodide uptake in thyroid [19, 29] in vivo and is
specifically accumulated in thyroid [18], reaching a high
thyroid to blood concentration ratio (at least 60:1 even at
low specific activities) [19]. It is hydrolytically stable under
physiological conditions [28] and is not significantly
metabolised [19]. TFB has low toxicity (rat LD50:
550 mg/kg when administered subcutaneously, according
to data from NaBF4 material safety data sheet). It is a
constituent of
99mTc-sestamibi kits for myocardial imaging
(78 μg/kit) and presents no hazard when intravenously
administered. It has been radiolabelled with
18F by isotopic
exchange under acidic conditions, although published
methods are not suitable for producing a radiotracer for
clinical PET [28]. Despite this potential, [
18F]TFB has not
been used for investigation of thyroid pathologies, or
indeed for PET imaging in any context. Today’s nuclear
medicine environment is better equipped, both to produce
this tracer and to exploit its potential imaging applications.
The relatively recent characterisation of cloned NIS [1, 20],
and its use in gene therapy, have created new applications
for NIS tracers. A simple and effective preparation of [
18F]
TFB could permit quantitative, high-resolution imaging of
NIS expression in this context without undue patient
radiation burden.
Materials and methods
Radiochemistry
Initial investigations of isotopic exchange labelling of
sodium tetrafluoroborate (Sigma-Aldrich, Gillingham, UK,
99%) were performed at various concentrations and temper-
atures with [
18F]fluoride, obtained directly from proton-
irradiated [
18O]water (97 atom%, Isochem Ltd., Hook, UK;
11 MeV protons from a CTI RDS 112 cyclotron, beam
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ion exchange, Kryptofix or azeotropic distillation. The pH
was modified using hydrochloric acid (Fisher Scientific,
Loughborough, UK).
Radioanalytical methods
Labelling was monitored by thin-layer chromatography
(TLC) using alumina TLC strips with fluorescent indicator
(length 100 mm, Sigma-Aldrich, Gillingham, UK) with
methanol as mobile phase. Strips were scanned using a
Mini-scan radio TLC scanner with Flow-Count detector
(LabLogic, Sheffield, UK). The presence of TFB at Rf
0.80–0.85 was demonstrated by scraping the alumina from
the TLC plate, extracting it with water and analysing by
anion LC-electrospray mass spectrometry (MS) (Agilent
6520 Accurate-Mass Q-TOF LC/MS, Agilent Technologies
UK Ltd.). A reverse UV HPLC method was developed
[Agilent 1200 series system with a quadruple pump, UV
detector (254 nm) and radioactivity detector (LabLogic,
Sheffield, UK)] utilising a SGE Exsil ODS (reverse phase)
column, 5 μm, 250×4.0 mm (SGE Europe Ltd., Bucks,
UK) with a mobile phase of 1 mM tetrabutylammonium
hydroxide and 1.3 mM potassium hydrogen phthalate in
water (pH 7.5) flowing at 1.0 ml/min, sample volume
20 μl. The method was validated by its ability to separate a
range of uninegative ions of similar size and lipophilicity
(in order of elution: fluoride, chloride, bromide, nitrate,
sulphate, iodide and tetrafluoroborate). The system was
calibrated to measure TFB concentration using standard
aqueous sodium tetrafluoroborate solutions. The elution
time of TFB and the identity of the eluted anion were
further confirmed by LC-MS analysis of fractions as above.
Synthesis of [
18F]TFB
From the above experiments the following automated (but
not fully optimised) labelling protocol was developed using
an Eckert and Ziegler Modular-Lab module (Imaging
Equipment Ltd., Bristol, UK). [
18F]fluoride (12–18 GBq)
was trapped by passage of the irradiated water (4 ml)
through a QMA (Waters UK, Elstree, UK) cartridge
conditioned with 1.0 M sodium hydrogen carbonate.
Hydrochloric acid (1.5 M, 1.2 ml), prepared by dilution of
5 M hydrochloric acid with water for injections (BP,
Hameln Pharmaceuticals, Gloucester, UK), was then passed
through, eluting the [
18F]fluoride into the reactor which
contained sodium tetrafluoroborate (1 mg in 0.1 ml 1.5 M
HCl). The reaction mixture (1.3 ml) was heated to 120°C
for 10 min, cooled to 25°C and passed through a silver ion-
loaded cation exchange cartridge (OnGuard II AG, Dionex,
Leeds, UK, conditioned with 10 ml water) to remove
chloride and raise the pH, and through two alumina
columns (Waters SepPak Light Alumina N, conditioned
with 10 ml water and 5 ml air, to remove unreacted [
18F]
fluoride) and a sterile Millex-GS 0.22 μm filter unit
(Millipore UK, Watford, UK), and washed through with a
further 2 ml water for injections, into a nitrogen-filled
sterile vial. The process, including irradiation, synthesis and
purification, takes less than 1 h. Analysis and quality
control were performed as described above before the
product was used in biological studies.
Stability/shelf life
The product was subjected to HPLC and TLC analysis as
described above after standing at room temperature for 5 h.
Serum stability
A total of 100 μl of the product was added to 1 ml human
serum (male, type AB, Sigma-Aldrich, Gillingham, UK)
and the mixture was incubated at 37°C. Aliquots (100 μl)
were withdrawn hourly up to 4 h into microcentrifuge tubes
and mixed with an equal volume of ethanol to precipitate
serum proteins. After centrifugation the supernatant was
analysed by HPLC and TLC as described above.
Cell culture
Media and reagents were obtained from PAA Laboratories
(Yeovil, UK) and hormones from Sigma-Aldrich (Poole,
UK). The Fisher rat thyroid cell line FRTL-5 was kindly
donated by Prof. Jan Smit and Dr. Guido Hovens (Leiden
University, The Netherlands) and grown in a humidified
incubator at 37°C with 5% CO2 in Hams:F12 medium
supplemented with 10% fetal bovine serum, penicillin/
streptomycin, minimal essential medium amino acids and a
hormone mixture containing insulin (10 μg/ml), hydrocor-
tisone (3.6 ng/ml), glycyl-histidyl-lysine acetate (10 ng/ml),
transferrin (5 μg/ml), somatostatin (10 ng/ml) and bovine
thyroid-stimulating hormone (TSH) (1 mU/ml). For experi-
ments without TSH stimulation, cells were maintained in
the same medium with all hormones except TSH for 7 days
prior to the experiment.
Tracer accumulation in FRTL-5 cells
Cells were seeded (150,000 per well, n=3 for each
treatment in each of two independent experiments) into
24-well plates (one plate for each time point, three wells for
each treatment) and incubated for 18–24 h. Prior to the
assay, cells were washed twice in 1 ml phosphate-buffered
saline (PBS), and Hanks’ balanced salt solution (HBSS,
500 μl) was added to each well with or without 10 μM
sodium perchlorate. The plate was incubated for 10 min
2110 Eur J Nucl Med Mol Imaging (2010) 37:2108–2116prior to the addition of 0.1 MBq [
18F]TFB (specific activity
10 GBq/mg) in a volume of 10 μl per well. At intervals
from 1 to 120 min the radioactive medium was aspirated
and cells were washed twice with 1 ml HBSS. Cell-bound
radioactivity was extracted by addition of 500 μl1M
NaOH for 10 min. Cell-associated activity was counted in a
gamma counter (Wallac 1282-001 Compugamma CS).
Accumulation was expressed as counts per minute (cpm)
per μg cellular protein, which was measured using a
Novagen bicinchoninic acid protein assay kit (Merck
Chemicals Ltd., Nottingham, UK).
Tracer efflux from FRTL-5 cells
Cells were seeded (150,000 per well) and incubated in 24-
well plates with triplicate wells for each time point as
described above. After addition of 0.1 MBq [
18F]TFB to
each well and incubation for 1 h, the radioactive medium
was removed and cells were washed twice in 1 ml HBSS
and 1 ml HBSS was added to each well. At intervals from 5
to 120 min the medium was collected and the activity
remaining in the cells was extracted with 1 M NaOH
(500 μl) for 10 min. Radioactivity was counted in HBSS
using a gamma counter. Radionuclide efflux was expressed
as the percentage of the total activity in cells immediately
after washing in HBSS.
Biodistribution
Animal studies were carried out in accordance with UK
Research Councils’ and Medical Research Charities’ guide-
lines on Responsibility in the Use of Animals in Bioscience
Research, under a UK Home Office licence. Female BALB/
c mice (n=3 per group, aged 9–12 weeks, 22.4±1.76 g)
were purchased from Harlan Laboratories, UK. One group
received i.p. injections of 50 μl PBS and another received
50 μl sodium perchlorate (Sigma-Aldrich, Gillingham, UK,
100 mg/ml) in PBS. After 30 min, both groups received i.v.
(tail vein) injections of approximately 3 MBq (50 μl) [
18F]
TFB (specific activity 10 GBq/mg). Animals were killed at
60 min post-injection (p.i.) and tissues explanted, blotted
dry, weighed (except thyroid, vide infra) and counted on a
gamma counter (the carcass activity was measured with an
ionisation chamber cross-calibrated with the gamma count-
er). Because of the small size and intimate attachment to
trachea, normal thyroid glands were explanted along with a
small piece of trachea and a standard thyroid tissue mass of
3.6 mg [30] used in all SUV calculations. A separate piece
of thyroid-free trachea was taken and weighed to confirm
that activity in trachea tissue did not significantly affect the
thyroid SUV calculation. A third group (n=4, range: 20.6±
1.53 g), treated as above without sodium perchlorate, were
killed at 30 min p.i. Uptake in each tissue was expressed as
SUV, calculated as activity (cpm) per gram of tissue divided
by total recovered activity (cpm) per gram of whole body
mass. Excreted radioactivity, radioactivity in the tail and
mass of the tail were excluded from the total recovered
activity.
Imaging
A BALB/c mouse (age and weight as above) and a TRβ
PV/PV
transgenic mouse [31] derived from a colony bred at King’s
College London (male, 11 months old, 27.8 g) received i.v.
(tail vein) injections of 5 MBq of [
18F]TFB (50 μl). With the
mice under isofluorane anaesthesia in a Minerve imaging
chamber, PET/CT scans were acquired 30 min p.i. using a
NanoPET/CT scanner (Bioscan, Paris, France) with PET
acquisition time 2,400 s, coincidence relation: 1-3; image
reconstruction: ordered subset expectation maximization
(OSEM) with single-slice rebinning (SSRB) 2-D line of
response (LOR), energy window: 400–600 keV, filter: Ram-
Lak cut-off 1, number of iterations/subsets: 8/6. The
biodistribution of the tracer in the TRβ
PV/PV mouse was then
determined ex vivo by dissection and organ counting after
sacrificing at 3.5 h p.i.
Results
Synthesis, purification and characterisation of [
18F]TFB
Initial experiments on exchange labelling of sodium
tetrafluoroborate with [
18F]fluoride showed that the reac-
tion rate and efficiency increased with increasing concen-
tration of TFB (Online Resource 1), increasing temperature
and increasing acid concentration, reaching a labelling
efficiency of 45% after 10 min at 75°C with a NaBF4
concentration of 10 mg/ml and HCl concentration of 1 M.
These initial experiments also yielded a TLC method able
to quantitatively distinguish [
18F]TFB (Rf 0.80–0.85) from
[
18F]fluoride (Rf 0) (Fig. 1). It was difficult to prove that
the radioactive spot at Rf 0.80–0.85 represents [
18F]TFB
using TLC alone since cold TFB has no chromophore.
However, electrospray MS confirmed the presence of TFB
in the Rf 0.80–0.85 fraction {87 and 86, 100% (M
−); and
197, 25% ([Na(BF4)2]
−)}. To support the identification of
labelled TFB, an HPLC method was developed and
validated by demonstrating reproducible separation of a
range of inorganic monoanions. In this method, [
18F]TFB
eluted between 6 and 7 min while [
18F]fluoride eluted at
3 min (Fig. 2). These times agreed with those determined
by spiking the radiotracer with the cold standards. [
18F]
fluoride was easily removed by passage through two
disposable alumina cartridges, eluting with water or saline,
as demonstrated using the TLC (Fig. 1) and HPLC (Fig. 2)
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biological evaluation, it was necessary to reduce the acidity
and chloride concentration without substantial dilution, for
which filtration through a Dionex AG (a cation exchanger
loaded with silver ions) cartridge proved efficacious, raising
the pH to between 6 and 7 without trapping [
18F]TFB.
Further development was conducted with use of an
automated synthesis apparatus. Labelling efficiency was
increased further by increasing the reaction temperature
(120°C) and time (20 min) and HCl concentration (1.5 M).
The specific activity of the product varied depending on the
starting activity of
18F. By starting with 12–18 GBq
18F and
1 mg sodium tetrafluoroborate, a specific activity of
10 GBq/mg (1 GBq/μmol) was routinely achieved, with
an isolated radiochemical yield of approximately 10%
uncorrected for decay in a volume of 2 ml. Radiochemical
purity consistently exceeded 96%. The pH was between 6
and 7. The production was complete within 30 min from
end of bombardment (EOB).
Shelf life and stability in serum
The speciation of radioactivity in the [
18F]TFB preparation,
as determined by TLC and HPLC, was unchanged after
standing at room temperature for 5 h. Similarly, incubation
in human serum at 37°C for 4 h gave no change in the TLC
or HPLC patterns.
In vitro accumulation in rat thyroid cells
[
18F]TFB showed rapid accumulation in NIS-expressing
FRTL-5 cells, reaching a plateau between 5 and 20 min.
The plateau count rate shown in Fig. 3 corresponds to an
intracellular to extracellular concentration ratio of approx-
imately 22:1. High accumulation was dependent on
pretreatment with TSH [32]. If TSH was excluded from
the medium for several days prior to the experiment,
accumulation was reduced by >90% under otherwise
identical conditions (Fig. 4). Accumulation by both TSH-
stimulated and untreated cells was dramatically inhibited
(approximately 90%) by sodium perchlorate (10 μM), a
well-established specific inhibitor of iodide uptake by hNIS
[33, 34] (Fig. 4). After pre-incubating cells in medium
containing [
18F]TFB, replacement of the medium with fresh
medium containing no [
18F]TFB led to rapid efflux of
tracer (more than 90% within 20 min).
In vivo biodistribution and imaging
The biodistribution of [
18F]TFB (Fig. 5) at 60 min p.i.
shows marked uptake in thyroid (mean SUV=71.9).
Stomach, which also is well known to express NIS [10],
also showed significant uptake (SUV=4.4) compared to
TFB
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Fig. 1 TLC of purified [
18F]TFB (upper) and [
18F]fluoride (lower)
using alumina stationary phase and methanol mobile phase, showing
their clear separation and the purity of the final product
purified
01234
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Fig. 2 Radio-HPLC of product of exchange
18F labelling of
tetrafluoroborate, before (upper) and after (lower) purification using
alumina column. For HPLC conditions see “Materials and methods”
section
2112 Eur J Nucl Med Mol Imaging (2010) 37:2108–2116other tissues. At 30 min p.i. thyroid uptake was slightly
higher (SUV=86; data not shown) than at 60 min. There
was no significant uptake in visceral organs or bones and
elimination was exclusively renal. To demonstrate that [
18F]
TFB uptake was mediated through NIS, a group of mice
receiving sodium perchlorate 30 min prior to [
18F]TFB
administration showed >95% suppression of [
18F]TFB
accumulation in thyroid (SUV=3.2) and stomach (SUV=
0.6) at 60 min. In the tumour-bearing TRβ
PV/PV mouse, with
greatly and symmetrically enlarged lobes of the thyroid
gland, the thyroid SUV (52 at 3.5 h p.i.) was reduced
compared to normal thyroid tissue but, nevertheless,
thyroid was by far the most radioactive organ.
As a preliminary assessment of the potential for PET
imaging, a BALB/c mouse was administered i.v. 5 MBq of
[
18F]TFB and imaged 30 min later. This gave clear images
of thyroid with high target to background ratio and both
lobes clearly resolved (Fig. 6). In addition to thyroid and
stomach, salivary glands were clearly visualised overlying
the thyroid glands. There was also accumulation in lateral
parts of the thorax which we attribute to mammary tissue.
High radioactivity in the bladder confirmed renal excretion
of the tracer. The images also showed that tissues not
specifically counted in the biodistribution experiments did
not have significant uptake, except salivary glands. A
TRβ
PV/PV transgenic mouse with a greatly enlarged spon-
taneous follicular thyroid tumour was also imaged and
despite lower thyroid SUV (52 at 3.5 h p.i.), the abnormal
morphology and increased volume were readily apparent
(Fig. 6). Accumulation in salivary glands, stomach,
mammary tissue and bladder was less evident in this
animal. This is consistent with clinical experience that
tissues with low hNIS expression such as thyroid cancer
metastases are often less evident when normally function-
ing thyroid or thyroid remnants are present.
Discussion
Early production of [
18F]TFB was limited by contemporary
methodology for producing
18F, which utilised the
16O(
3H,
n)
18Fo r
18O(p,n)
18F reactions on natural abundance
Li2CO3 or
18O-enriched Li2CO3, using a Van der Graaf
generator. An exchange reaction of
18F-fluoride with
potassium tetrafluoroborate in acid (pH 0) at room
TFB uptake in FRTL-5 cells
0
100000
200000
300000
400000
500000
600000
700000
– perchlorate + perchlorate
c
p
m
/
m
g
 
p
r
o
t
e
i
n
– TSH + TSH
Fig. 4 Effect of perchlorate and TSH on plateau accumulation of
[
18F]TFB in FRTL-5 rat thyroid cells (n=3,error bars represent 1 SD)
TFB uptake in FRTL5 cells
0
50
100
150
200
250
300
0 2 04 06 08 01 0 0 1 2 0
time/min
c
p
m
/
u
g
 
p
r
o
t
e
i
n
perchlorate-
perchlorate+
TFB efflux from FRTL5 cells
0
20
40
60
80
100
0 20 40 60 80 100 120
time/min
%
 
r
e
t
e
n
t
i
o
n
Fig. 3 Upper panel Accumulation of [
18F]TFB in FRTL-5 rat thyroid
cells, with and without blocking with perchlorate. Lower panel Efflux
of radioactivity from FRTL-5 cells after treatment with [
18F]TFB
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18F]KBF4, which was purified
by recrystallisation [18, 28], a method which inherently
leads to low specific activity. The route described here is
similar in principle, but with modern methods for
18F
production and a new purification method, efficient
production is possible to give higher specific activity [
18F]
TFB adequate for imaging in humans while avoiding
saturation of NIS in vivo. This required a compromise
between the best % radiochemical yield and the best
specific activity. A satisfactory compromise is described
here although some features of the method remain open to
significant further optimisation. The neutralisation step
involves removal of HCl by displacing Ag
+ from a cation
exchange resin, with precipitation of AgCl on the column, a
method previously applied to
99mTc generator eluates [35].
This raises the pH from 0 to between 6 and 7. The
purification method exploits the affinity of fluoride ions for
an alumina Sep-Pak cartridge. The method is easily adapted
to GMP production. The processing was simple and
complete within 30 min from EOB to readiness for quality
control and administration. Quality control was performed
using HPLC and TLC. The TLC method described is ideal
for routine determination of radiochemical purity of the
GMP product. The chromatographic behaviour of the
radioactive species identified it as tetrafluoroborate. The
final pH, volume and composition are compatible with
clinical use. The radiopharmaceutical has a shelf life and
serum stability at least commensurate with the physical
half-life of
18F, placing no limitations on clinical use.
The rapid uptake and efflux of [
18F]TFB in the rat
thyroid cell line parallels the behaviour of [
99mTc]pertech-
netate (Online Resource 1), which is known to be taken up
in cells expressing NIS [23, 36]. The plateau per cent
accumulation represents an intracellular to extracellular
concentration ratio of 22:1. The rapid efflux on removal
of TFB from the supernatant indicates that radioactivity is
not irreversibly trapped. It also implies that the washing
steps employed before measurement of uptake would have
washed out a significant fraction of the cellular radioactiv-
ity, and hence the measured plateau intracellular to
extracellular [
18F]TFB concentration ratio is likely to
significantly underestimate the true ratio. It is clear from
the TSH stimulation of uptake, and blocking by perchlorate,
that uptake of [
18F]TFB is specific and mediated by NIS.
TSH is known to upregulate NIS activity in thyroid cells
[32, 37], and perchlorate is a known specific inhibitor of
NIS [20, 23, 33]. At a specific activity of 10 GBq/mg the
TFB concentration in the wells was about 0.2 μM. This is
within the range of the measured IC50 for inhibition of NIS-
mediated iodide uptake [29], and hence uptake may
increase at higher specific activity. Nevertheless, the data
provide justification for in vivo biological evaluation of
[
18F]TFB.
The biodistribution of [
18F]TFB in normal mice and in a
TRβ
PV/PV mouse (a transgenic mouse with the “knock-in”
PV mutation that spontaneously develops follicular thyroid
cancer [31]) was investigated to evaluate its potential use as
a tool to image thyroid disease. The SUV in normal thyroid
may be subject to systematic error because “standard”
weights were used in the calculations; values for standard
weights of mouse thyroids ranging from 1.6 to 5 mg have
been used by previous authors [30, 38, 39]. The most
apparently rigorous measurements were reported by Rugh
[30] and we used the value of 3.6 mg accordingly.
Nevertheless, we can be confident that the high and specific
accumulation of [
18F]TFB in normal thyroid (SUV>70 at
Fig. 6 PET/CT images. Left
and centre Anterior (left) and
lateral (centre, to distinguish
thyroid from salivary gland
uptake) view maximum intensi-
ty projections of normal mouse
30 min after injection of [
18F]
TFB. Right PET/CT image of
TRβ
PV/PV transgenic mouse with
thyroid tumour, 30 min after
injection with [
18F]TFB
2114 Eur J Nucl Med Mol Imaging (2010) 37:2108–21161 h, higher at 30 min), stomach and salivary glands [10, 23,
40], and rapid renal clearance, parallel the behaviour of
[
99mTc]pertechnetate. The lack of significant uptake in bone
is consistent with the expectation from the observed
stability in serum that fluoride ion is not released in vivo.
These pharmacokinetic attributes are very similar to those
of [
99mTc]pertechnetate (Online Resource 1) and are ideal
for PET imaging, providing a good match with the half-life
of
18F and offering favourable dosimetry and imaging
convenience in humans. The PET/CT images confirm this
and show no uptake in bones or joints; hence, there is no in
vivo release of [
18F]fluoride. Accumulation in thyroid
tumour tissue of the TRβ
PV/PV mouse was also marked
and indicates the potential value of thyroid tumour imaging
with this tracer. The SUV was somewhat reduced compared
to that of the normal thyroid tissue; however, this may be
because the animal was killed at a later time point (3.5 h)
than the normal mice.
The preliminary PET/CT images shown here represent
the first biological imaging data produced with this model
of scanner and demonstrate the excellent resolution and
sensitivity of the instrument. Full evaluation of the
technical capability of the instrument will be published in
due course. The two lobes (each <2 mg) of the normal
mouse thyroid are clearly resolved and the altered mor-
phology of the thyroid tumour is clearly evident. The
imaging quality supports the precept that a
18F-labelled
tracer for NIS has potential to improve radionuclide
imaging of thyroid disease.
The present data are not able to show whether TFB ions
are transported into cells by NIS, or whether they merely
occupy a binding site. Previously published data show that
a transmembrane potential is generated during iodide
transport by NIS, consistent with symport of two sodium
ions per iodide. The transmembrane potential generated by
TFB (and of other competitors such as pertechnetate and
perrhenate) is much smaller [2], indicating either that TFB
transport occurs with little or no coupling to sodium
transport, or that TFB occupies a binding site on NIS but
is transported very inefficiently.
Without further optimisation, the present synthesis
generates a product with a modest specific activity of
10 GBq/mg (1 GBq/μmol) when starting with 12–
18 GBq
18F. A likely scenario for production for human
use is as follows. Starting with 10 GBq
18F, assuming 50%
incorporation of
18F into TFB and a production time of
30 min, the specific activity at the time of injection would
b ei nt h eo r d e ro f5G B q / m gT F Bo r0 . 5G B q / μmol. An
administered activity of 400 MBq would thus contain
0.8 μmol TFB. This does not present a significant toxicity
hazard (a commercial kit for the preparation of [
99mTc]
sestamibi contains about this amount). However, upon
dilution into the vascular and interstitial compartment the
initial concentration in vivo to which NIS is exposed
would be in the order of 0.1 μM. The IC50 of TFB for
inhibition of iodide uptake by NIS is between 0.1 and
1 μM[ 29]. Thus, although the images and biodistribution
show that the specific activity is clearly adequate for
thyroid imaging purposes, optimisation to improve the
specific activity perhaps tenfold, preferably without start-
ing with excessive activity of
18F ,m i g h tw e l lp r o v i d ea
superior target to background ratio.
Conclusion
We report a simple synthesis of [
18F]TFB, with sufficient
specific activity for imaging the sodium/iodide symporter in
vivo. Preliminary biological assessment shows behaviour
very similar to that of
99mTc-pertechnetate and justifies
evaluation of [
18F]TFB in humans. It may find applications
in pre- and post-surgical evaluation of primary thyroid
malignancy and detection of metastases, and for imaging
expression of hNIS as a reporter gene, offering the
possibility of improved image quality and quantification
compared to
99mTc-pertechnetate at the expense of a higher
effective radiation dose per injected activity.
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